vs
EXACT SCIENCES CORP（EXAS）与PIPER SANDLER COMPANIES（PIPR）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是PIPER SANDLER COMPANIES的1.3倍（$878.4M vs $667.0M），PIPER SANDLER COMPANIES净利率更高（17.1% vs -9.8%，领先26.9%），PIPER SANDLER COMPANIES同比增速更快（37.4% vs 23.1%），过去两年PIPER SANDLER COMPANIES的营收复合增速更高（39.2% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Piper Sandler是一家美国跨国投资银行及金融服务提供商，核心业务覆盖并购重组、财务重整、公开募股、公共财政、机构经纪、投资管理、证券研究等领域，通过旗下核心子公司Piper Sandler & Co.为企业、机构投资者及公共组织提供专业金融服务。
EXAS vs PIPR — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$667.0M
营收增速更快
PIPR
高出14.3%
23.1%
净利率更高
PIPR
高出26.9%
-9.8%
两年增速更快
PIPR
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $667.0M |
| 净利润 | $-86.0M | $114.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 28.3% |
| 净利率 | -9.8% | 17.1% |
| 营收同比 | 23.1% | 37.4% |
| 净利润同比 | 90.1% | 65.0% |
| 每股收益（稀释后） | $-0.45 | $6.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPIPR
| Q4 25 | $878.4M | $667.0M | ||
| Q3 25 | $850.7M | $480.1M | ||
| Q2 25 | $811.1M | $398.6M | ||
| Q1 25 | $706.8M | $358.6M | ||
| Q4 24 | $713.4M | $485.4M | ||
| Q3 24 | $708.7M | $360.9M | ||
| Q2 24 | $699.3M | $340.8M | ||
| Q1 24 | $637.5M | $344.4M |
净利润EXASPIPR
| Q4 25 | $-86.0M | $114.0M | ||
| Q3 25 | $-19.6M | $60.3M | ||
| Q2 25 | $-1.2M | $42.2M | ||
| Q1 25 | $-101.2M | $64.9M | ||
| Q4 24 | $-864.6M | $69.1M | ||
| Q3 24 | $-38.2M | $34.8M | ||
| Q2 24 | $-15.8M | $34.8M | ||
| Q1 24 | $-110.2M | $42.5M |
毛利率EXASPIPR
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASPIPR
| Q4 25 | -9.4% | 28.3% | ||
| Q3 25 | -3.0% | 22.4% | ||
| Q2 25 | -0.3% | 12.3% | ||
| Q1 25 | -13.6% | 8.2% | ||
| Q4 24 | -122.8% | 16.9% | ||
| Q3 24 | -5.6% | 15.4% | ||
| Q2 24 | -3.8% | 8.3% | ||
| Q1 24 | -16.7% | 15.2% |
净利率EXASPIPR
| Q4 25 | -9.8% | 17.1% | ||
| Q3 25 | -2.3% | 12.6% | ||
| Q2 25 | -0.1% | 10.6% | ||
| Q1 25 | -14.3% | 18.1% | ||
| Q4 24 | -121.2% | 14.2% | ||
| Q3 24 | -5.4% | 9.6% | ||
| Q2 24 | -2.3% | 10.2% | ||
| Q1 24 | -17.3% | 12.3% |
每股收益（稀释后）EXASPIPR
| Q4 25 | $-0.45 | $6.41 | ||
| Q3 25 | $-0.10 | $3.38 | ||
| Q2 25 | $-0.01 | $2.38 | ||
| Q1 25 | $-0.54 | $3.65 | ||
| Q4 24 | $-4.69 | $3.88 | ||
| Q3 24 | $-0.21 | $1.96 | ||
| Q2 24 | $-0.09 | $1.97 | ||
| Q1 24 | $-0.60 | $2.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.4B |
| 总资产 | $5.9B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPIPR
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | — |
股东权益EXASPIPR
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $3.2B | $1.2B | ||
| Q2 24 | $3.2B | $1.1B | ||
| Q1 24 | $3.1B | $1.1B |
总资产EXASPIPR
| Q4 25 | $5.9B | $2.6B | ||
| Q3 25 | $5.9B | $2.2B | ||
| Q2 25 | $5.8B | $2.0B | ||
| Q1 25 | $5.7B | $1.8B | ||
| Q4 24 | $5.9B | $2.3B | ||
| Q3 24 | $6.7B | $2.0B | ||
| Q2 24 | $6.7B | $1.9B | ||
| Q1 24 | $6.4B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $729.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 6.40× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASPIPR
| Q4 25 | $151.7M | $729.8M | ||
| Q3 25 | $219.9M | $31.9M | ||
| Q2 25 | $89.0M | $32.1M | ||
| Q1 25 | $30.8M | $-207.2M | ||
| Q4 24 | $47.1M | $163.8M | ||
| Q3 24 | $138.7M | $80.1M | ||
| Q2 24 | $107.1M | $266.5M | ||
| Q1 24 | $-82.3M | $-197.2M |
自由现金流EXASPIPR
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASPIPR
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASPIPR
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASPIPR
| Q4 25 | — | 6.40× | ||
| Q3 25 | — | 0.53× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | — | -3.19× | ||
| Q4 24 | — | 2.37× | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 7.66× | ||
| Q1 24 | — | -4.64× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PIPR
| Advisory Services | $402.6M | 60% |
| Equities Financing | $66.7M | 10% |
| Equity Salesand Trading | $64.2M | 10% |
| Fixed Income Salesand Trading | $47.9M | 7% |
| Other | $46.7M | 7% |
| Debt Financing | $38.9M | 6% |
